Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05387148
Registration number
NCT05387148
Ethics application status
Date submitted
15/05/2022
Date registered
24/05/2022
Date last updated
3/06/2022
Titles & IDs
Public title
The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence
Query!
Scientific title
The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence: An Exploratory Pilot Study
Query!
Secondary ID [1]
0
0
X19-0416
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alcohol Use Disorder (AUD)
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Addiction
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cannabidiol (CBD)
Treatment: Drugs - Placebo
Experimental: Cannabidiol (CBD) - For a total of three days, so that both study participants and staff are blind to treatment condition
Placebo Comparator: Placebo - For a total of three days, so that both study participants and staff are blind to treatment condition
Treatment: Drugs: Cannabidiol (CBD)
Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.
Treatment: Drugs: Placebo
The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Changes in High Frequency Heart Rate Variability
Query!
Assessment method [1]
0
0
To assess whether acute ingestion of CBD can modulate heart rate variability when responding to alcohol cues compared to neutral cues
Query!
Timepoint [1]
0
0
22 days
Query!
Primary outcome [2]
0
0
Changes in Skin Conductance Levels
Query!
Assessment method [2]
0
0
To assess whether acute ingestion of CBD modulates skin conductance levels when responding to alcohol cues compared to neutral cues
Query!
Timepoint [2]
0
0
22 days
Query!
Primary outcome [3]
0
0
Changes in Brain Activation
Query!
Assessment method [3]
0
0
To assess whether acute ingestion of CBD can attenuate brain activation via blood oxygen level dependent (BOLD) in areas associated with alcohol cue-elicited craving measured by an fMRI machine
Query!
Timepoint [3]
0
0
22 days
Query!
Primary outcome [4]
0
0
Changes in Neurotransmitter levels in the Brain
Query!
Assessment method [4]
0
0
To assess whether CBD treatment leads to changes in brain levels of the neurotransmitters: glutamate, gamma-aminobutyric acid (GABA), N-acetylaspartate (NAA) and glutathione (GSH)
Query!
Timepoint [4]
0
0
22 days
Query!
Primary outcome [5]
0
0
Heavy Drinking Days
Query!
Assessment method [5]
0
0
Reduction in Heavy Drinking Days (HDD; defined as 4 or more drinks in a day for women and five or more drinks in a day for men). This will be measured by the Timeline Follow Back.
Query!
Timepoint [5]
0
0
Up to 43 days
Query!
Primary outcome [6]
0
0
Absence of any Heavy Drinking Day
Query!
Assessment method [6]
0
0
Measured by Timeline Follow Back
Query!
Timepoint [6]
0
0
Up to 43 days
Query!
Primary outcome [7]
0
0
Mean Alcohol Consumption per Drinking Day
Query!
Assessment method [7]
0
0
Measured by Timeline Follow Back
Query!
Timepoint [7]
0
0
Up to 43 days
Query!
Primary outcome [8]
0
0
Alcohol Dependence Severity
Query!
Assessment method [8]
0
0
Measured by the Alcohol Dependence Scale. The minimum score is 0 and the maximum score is 47. A higher score indicates more severe dependence.
Query!
Timepoint [8]
0
0
Baseline
Query!
Primary outcome [9]
0
0
Alcohol Craving
Query!
Assessment method [9]
0
0
As measured by the Penn Alcohol Craving Scale (PACS), which measures the amount of time spent thinking and craving for alcohol, difficulty in resisting consumption of alcohol if present and hypothetical pleasure associated with consumption of alcohol. This scale has a minimum score of 0 and a maximum score of 6. A higher score indicates greater levels of craving.
Query!
Timepoint [9]
0
0
Up to 43 days
Query!
Secondary outcome [1]
0
0
Changes in Alcohol Craving
Query!
Assessment method [1]
0
0
To assess whether acute ingestion of CBD can modulate subjective measures of alcohol cue elicited craving. This will be measured during the fMRI scan using the Visual Analogue Scale. This scale will assess alcohol craving, thirst and anxiety.
Query!
Timepoint [1]
0
0
22 days
Query!
Secondary outcome [2]
0
0
Changes in Alcohol Craving in response to alcohol cues
Query!
Assessment method [2]
0
0
To assess whether acute ingestion of CBD can modulate subjective measures of alcohol cue elicited craving. This will be measured before and after the fMRI scan using the Alcohol Urge Questionnaire (AUQ). This Questionnaire consists of 8 questions that are scored on a Likert scale of 7 points. Two of the questions are reversed scored. Total score is computed by averaging the item scores. A greater score indicates greater craving.
Query!
Timepoint [2]
0
0
22 days
Query!
Secondary outcome [3]
0
0
Changes in Positive and Negative Mood States
Query!
Assessment method [3]
0
0
To assess whether acute ingestion of CBD can modulate subjective measures of positive and negative mood states following alcohol cues. This will be measured before and after the fMRI scan using the Positive and Negative Affect Schedule (PANAS).
Query!
Timepoint [3]
0
0
22 days
Query!
Secondary outcome [4]
0
0
Changes in Anxiety
Query!
Assessment method [4]
0
0
Measured by cumulative scores on the DASS-21 Anxiety Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more anxiety.
Query!
Timepoint [4]
0
0
Up to 43 days
Query!
Secondary outcome [5]
0
0
Changes in Depression
Query!
Assessment method [5]
0
0
Measured by cumulative scores on the DASS-21 Depression Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates greater depression.
Query!
Timepoint [5]
0
0
Up to 43 days
Query!
Secondary outcome [6]
0
0
Changes in Stress
Query!
Assessment method [6]
0
0
Measured by cumulative scores on the DASS-21 Stress Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more stress.
Query!
Timepoint [6]
0
0
Up to 43 days
Query!
Secondary outcome [7]
0
0
Sleep Disturbances
Query!
Assessment method [7]
0
0
As measured by the ISI (Insomnia Severity Index). This Index has a minimum score of 0 and a maximum score of 28. The higher the score indicates more severe insomnia.
Query!
Timepoint [7]
0
0
Up to 43 days
Query!
Secondary outcome [8]
0
0
Sleep Disturbances
Query!
Assessment method [8]
0
0
To assess whether acute ingestion of CBD has any impact of sleep. This will be measured by an Actiwatch. The Actiwatch records motion and light to determine information about participants sleep and wake patterns. The participants will wear this watch for 48 hours on two separate occasions.
Query!
Timepoint [8]
0
0
22 days
Query!
Secondary outcome [9]
0
0
Changes in Tension Reduction Alcohol Expectancies
Query!
Assessment method [9]
0
0
To assess whether CBD treatment can reduce participants need to use alcohol to attenuate tension states (such as anxiety) as measured by the Tension Reduction subscale of the Alcohol Expectancy Questionnaire. Higher scores indicate greater reliance on alcohol to reduce tension/ anxiety.
Query!
Timepoint [9]
0
0
Up to 43 days
Query!
Secondary outcome [10]
0
0
Lifetime Consequences related to Drinking
Query!
Assessment method [10]
0
0
To examine the adverse consequences a participant has experienced in their lifetime due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Lifetime Edition (DrInC-2L). Higher scores indicate more consequences.
Query!
Timepoint [10]
0
0
Baseline
Query!
Secondary outcome [11]
0
0
Recent Consequences related to Drinking
Query!
Assessment method [11]
0
0
To examine the adverse consequences a participant has experienced in the last 3 months due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Recent Edition (DrInC-2R). Higher scores indicate more consequences.
Query!
Timepoint [11]
0
0
Baseline
Query!
Secondary outcome [12]
0
0
Behavioural Inhibition/Avoidance Scales
Query!
Assessment method [12]
0
0
The BIS/BAS Scale is a 20-item self-report questionnaire designed to measure two motivational systems: the behavioral inhibition system (BIS), which corresponds to motivation to avoid aversive outcomes, and the behavioral activation system (BAS), which corresponds to motivation to approach goal-oriented outcomes.
Query!
Timepoint [12]
0
0
22 days
Query!
Secondary outcome [13]
0
0
Obsessive Compulsive Drinking
Query!
Assessment method [13]
0
0
To assess an individuals obsessive thoughts about alcohol use and compulsive behaviours towards drinking as measured by the Obsessive Compulsive Drinking Scale. Six of the questions measure to obsession and eight of the questions measure compulsivity. Higher scores on these subscales indicate more obsession and compulsion, respectively.
Query!
Timepoint [13]
0
0
22 days
Query!
Secondary outcome [14]
0
0
Self-Confidence to Remain Abstinent
Query!
Assessment method [14]
0
0
To measure an individual's self-confidence in avoiding alcohol through the Alcohol Abstinence Self-Efficacy Scale (AASE). There are 20 questions and each is scored from 0 to 4. Higher scores on this scale indicate more self-confidence.
Query!
Timepoint [14]
0
0
22 days
Query!
Secondary outcome [15]
0
0
Intolerance of Uncertainty
Query!
Assessment method [15]
0
0
To assess an individual's reactions to situations that are ambiguous, the consequences of being uncertain, and attempts the individual might make to control the future. This will be measured through the Intolerance of Uncertainty Scale (IUS). This scale includes 27-items that are scored on a Likert scale (1 - Not at all characteristic of me to 5 - entirely characteristic of me). All scores are summed up and a higher score indicates greater inability to deal with uncertainty.
Query!
Timepoint [15]
0
0
22 days
Query!
Secondary outcome [16]
0
0
Impulsivity
Query!
Assessment method [16]
0
0
To assess an individual's impulsivity across four domains: urgency, lack of premeditation and perseverance, and sensation seeking. This will be measured through the Impulsivity Scale (UPPS). Greater scores on this scale indicate greater impulsivity.
Query!
Timepoint [16]
0
0
22 days
Query!
Secondary outcome [17]
0
0
Alcohol Withdrawal
Query!
Assessment method [17]
0
0
To assess an individual's severity of alcohol withdrawal through the Clinical Institute Withdrawal Assessment of Alcohol Scale - Revised (CIWA-Ar). Greater scores on this scale indicate the participant is experiencing greater alcohol withdrawal symptoms.
Query!
Timepoint [17]
0
0
22 days
Query!
Secondary outcome [18]
0
0
Approach and Avoidance towards Alcohol
Query!
Assessment method [18]
0
0
To assess an individual's automatic action tendencies (either approve or avoid) towards alcohol. This will be measured through the Approach Avoidance Task (AAT).
Query!
Timepoint [18]
0
0
Up to 43 days
Query!
Secondary outcome [19]
0
0
Response Time and Visuospatial Skills
Query!
Assessment method [19]
0
0
To assess an individual's response time and visuospatial skills through the Trail Making Test Part A (TMT-A).
Query!
Timepoint [19]
0
0
Up to 43 days
Query!
Secondary outcome [20]
0
0
Set-shifting Flexibility, Attention, and Inhibition
Query!
Assessment method [20]
0
0
To assess an individual's set-shifting flexibility, attention and inhibition through the Trail Making Test Part B (TMT-B).
Query!
Timepoint [20]
0
0
Up to 43 days
Query!
Secondary outcome [21]
0
0
Risk/Reward Taking Behaviour
Query!
Assessment method [21]
0
0
To assess an individual's risk taking behaviour measured through the Balloon Analogue Risk Task (BART).
Query!
Timepoint [21]
0
0
Up to 43 days
Query!
Secondary outcome [22]
0
0
Decision Making
Query!
Assessment method [22]
0
0
To assess an individual's decision making skills measured through the Columbia Card Task (CCT).
Query!
Timepoint [22]
0
0
Up to 43 days
Query!
Secondary outcome [23]
0
0
Response Inhibition
Query!
Assessment method [23]
0
0
To assess an individual's ability to inhibit prepotent responses measured through the Stroop task.
Query!
Timepoint [23]
0
0
Up to 43 days
Query!
Secondary outcome [24]
0
0
Working Memory Capacity to Update Information
Query!
Assessment method [24]
0
0
To assess an individual's capacity to update working memory information measured through the N-back task.
Query!
Timepoint [24]
0
0
Up to 43 days
Query!
Secondary outcome [25]
0
0
Working Memory Capacity to Shift Information
Query!
Assessment method [25]
0
0
To assess an individual's capacity to shift between two tasks measured by the Number Letter task.
Query!
Timepoint [25]
0
0
Up to 43 days
Query!
Secondary outcome [26]
0
0
Markers of neuroinflammation
Query!
Assessment method [26]
0
0
As measured by differences in blood sampling levels of glutathione.
Query!
Timepoint [26]
0
0
Up to 43 days
Query!
Secondary outcome [27]
0
0
Markers of Stress
Query!
Assessment method [27]
0
0
As measured by differences in blood sampling levels of cortisol. This will be measured at rest, before the fMRI scan and following the fMRI scan.
Query!
Timepoint [27]
0
0
Up to 43 days
Query!
Eligibility
Key inclusion criteria
- Male and female patients between ages of 18 and 65 meeting DSM-5 criteria for current
alcohol use disorder
- Adequate cognition and English language skills to give valid consent and complete
research interviews;
- A BrAC reading of 0.00
- Must have a stable residence and be able to identify an individual who could locate
subject if needed
- Provision of informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Active major psychological disorder associated with psychosis, significant suicide
risk
- Pregnancy or lactation - women shall be advised to use reliable contraception for the
duration of drug therapy and a urine pregnancy test will be performed where necessary;
- Dependence on any substance other than nicotine (eg methadone)
- Diagnosis of epilepsy, and/or current use of anti-epileptic drugs (AED)
- Liver failure with jaundice or prolonged INR above 1.3
- Medical complications such as liver failure, cardiac ischemia or conduction
abnormalities, renal impairment or unstable elevated vital signs (systolic blood
pressure > 180, diastolic blood pressure > 120 or heart rate > 150)
- Severe cognitive impairment or insufficient English or literacy to complete study
processes
- Concurrent use of drugs potentially exacerbated by CBD via CYP3A5 including cardiac
medication (e.g. betablockers, calcium channel blockers and statins), macrolides and
recent antihistamine use.
- Claustrophobia;
- Extreme obesity;
- Previous brain surgery;
- Ever employed as a machinist, a welder or a metal worker;
- Metal items such as pacemakers; aneurysm clips in the brain; metal dental implants;
metallic fragments in the eye or anywhere else; insulin pump; metal implants; hearing
aid or a prosthetic device.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Unknown status
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
1/06/2022
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/06/2024
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Drug Health Services, Royal Prince Alfred Hospital - Sydney
Query!
Recruitment postcode(s) [1]
0
0
2050 - Sydney
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
South West Sydney Local Health District
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
University of Sydney
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Lambert Initiative for Cannabinoid Therapeutics
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study will explore the psychophysiological and neurobiological and mechanisms of CBD in
participants with alcohol use disorder
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05387148
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Kirsten Morley, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61295153636
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05387148
Download to PDF